Pluristem Therapeutics, Inc. (PSTI)
-NasdaqCM | Prev Close: | 3.45 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.08 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.47 - 4.17 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 141,183 |
|---|
| Market Cap: | 204.18M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to IsraelGlobeNewswire(Wed 4:00AM EDT)
- Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host DiseaseGlobeNewswire(Tue, Oct 1)
- Good News for Pluristem, Shares UpZacks(Tue, Sep 17)
- PLURISTEM THERAPEUTICS INC FinancialsEDGAR Online Financials(Tue, Sep 17)
- PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other EventsEDGAR Online(Mon, Sep 16)
- Stocks to Watch: Boise, Qihoo, Pluristemat The Wall Street Journal(Mon, Sep 16)
- Pluristem Therapeutics upgraded by Maxim GroupBriefing.com(Mon, Sep 16)
- FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication StudyGlobeNewswire(Mon, Sep 16)
- A Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Company: Oncology and Orphan Drugs Retain Pricing PowerWall Street Transcript(Fri, Sep 13)
- Loss Widens at PluristemZacks(Thu, Sep 12)
- Celgene's And Osiris' IP Positions Weakened By Pluristem's Pivotal Patentat Seeking Alpha(Thu, Sep 12)
- PLURISTEM THERAPEUTICS INC Files SEC form 10-K, Annual ReportEDGAR Online(Wed, Sep 11)
- Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery DiseaseGlobeNewswire(Wed, Sep 11)
- Novartis Ties Up With RegenerexZacks(Tue, Sep 10)
- Biotech: A Scattershot Of Stem Cell Plays Following Yesterday's Bloodbathat Seeking Alpha(Tue, Aug 27)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 300.71 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-14)
: | -0.51 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases.
View More
0.41%